259 related articles for article (PubMed ID: 9915812)
21. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
Burkey TH; Quock RM; Consroe P; Ehlert FJ; Hosohata Y; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Oct; 336(2-3):295-8. PubMed ID: 9384246
[TBL] [Abstract][Full Text] [Related]
22. Functional role of high-affinity anandamide transport, as revealed by selective inhibition.
Beltramo M; Stella N; Calignano A; Lin SY; Makriyannis A; Piomelli D
Science; 1997 Aug; 277(5329):1094-7. PubMed ID: 9262477
[TBL] [Abstract][Full Text] [Related]
23. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine.
Ross RA; Brockie HC; Fernando SR; Saha B; Razdan RK; Pertwee RG
Br J Pharmacol; 1998 Nov; 125(6):1345-51. PubMed ID: 9863666
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effects of cannabinoid receptor ligands on electrically-evoked responses in rat isolated tracheal ring segments.
Yousif MH; Oriowo MA
Pharmacol Res; 1999 Nov; 40(5):415-21. PubMed ID: 10527656
[TBL] [Abstract][Full Text] [Related]
25. Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Aug; 56(2):132-9. PubMed ID: 17574859
[TBL] [Abstract][Full Text] [Related]
26. Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells.
Lau AH; Chow SS
Eur J Pharmacol; 2003 Mar; 464(2-3):229-35. PubMed ID: 12620517
[TBL] [Abstract][Full Text] [Related]
27. The cannabinoid agonist WIN 55,212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells.
Nilsson O; Fowler CJ; Jacobsson SO
Eur J Pharmacol; 2006 Oct; 547(1-3):165-73. PubMed ID: 16928371
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens.
Ross RA; Gibson TM; Brockie HC; Leslie M; Pashmi G; Craib SJ; Di Marzo V; Pertwee RG
Br J Pharmacol; 2001 Feb; 132(3):631-40. PubMed ID: 11159715
[TBL] [Abstract][Full Text] [Related]
29. CB1 cannabinoid receptor-mediated cell migration.
Song ZH; Zhong M
J Pharmacol Exp Ther; 2000 Jul; 294(1):204-9. PubMed ID: 10871313
[TBL] [Abstract][Full Text] [Related]
30. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
Lin S; Khanolkar AD; Fan P; Goutopoulos A; Qin C; Papahadjis D; Makriyannis A
J Med Chem; 1998 Dec; 41(27):5353-61. PubMed ID: 9876105
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats.
Di Marzo V; Berrendero F; Bisogno T; González S; Cavaliere P; Romero J; Cebeira M; Ramos JA; Fernández-Ruiz JJ
J Neurochem; 2000 Apr; 74(4):1627-35. PubMed ID: 10737621
[TBL] [Abstract][Full Text] [Related]
32. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures.
Molina-Holgado F; Molina-Holgado E; Guaza C; Rothwell NJ
J Neurosci Res; 2002 Mar; 67(6):829-36. PubMed ID: 11891798
[TBL] [Abstract][Full Text] [Related]
33. Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2-arachidonoylglycerol.
Oka S; Wakui J; Gokoh M; Kishimoto S; Sugiura T
Eur J Pharmacol; 2006 May; 538(1-3):154-62. PubMed ID: 16647054
[TBL] [Abstract][Full Text] [Related]
34. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Sep; 56(3):185-92. PubMed ID: 17656103
[TBL] [Abstract][Full Text] [Related]
35. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain.
Sugiura T; Kondo S; Sukagawa A; Nakane S; Shinoda A; Itoh K; Yamashita A; Waku K
Biochem Biophys Res Commun; 1995 Oct; 215(1):89-97. PubMed ID: 7575630
[TBL] [Abstract][Full Text] [Related]
36. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.
Darmani NA
J Pharmacol Exp Ther; 2002 Jan; 300(1):34-42. PubMed ID: 11752094
[TBL] [Abstract][Full Text] [Related]
37. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
Pan X; Ikeda SR; Lewis DL
Mol Pharmacol; 1998 Dec; 54(6):1064-72. PubMed ID: 9855635
[TBL] [Abstract][Full Text] [Related]
38. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
39. Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices.
Ameri A; Wilhelm A; Simmet T
Br J Pharmacol; 1999 Apr; 126(8):1831-9. PubMed ID: 10372827
[TBL] [Abstract][Full Text] [Related]
40. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
